Novartis Ag (NVSEF) Interest Expenses (2009 - 2026)

Novartis Ag has disclosed Interest Expenses across 16 years of filings, most recently posting -$343.0 million for Q1 2026.

• Interest Expenses for Q1 2026 came in at -$343.0 million, down 27.04% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.2 billion (down 15.36% YoY), and the FY2025 annual result was $1.1 billion, up 13.72% from the prior year.
• Interest Expenses came in at -$343.0 million for Q1 2026 at Novartis Ag, down from -$304.0 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of -$200.0 million in Q1 2023 to a low of -$343.0 million in Q1 2026.
• The 5-year median for Interest Expenses is -$222.0 million (2023), against an average of -$244.9 million.
• Across the five-year window, Interest Expenses advanced 0.5% in 2023 and slipped 27.04% in 2026, its largest moves.
• Novartis Ag's Interest Expenses stood at -$207.0 million in 2022, then fell by 4.83% to -$217.0 million in 2023, then decreased by 26.73% to -$275.0 million in 2024, then declined by 10.55% to -$304.0 million in 2025, then declined by 12.83% to -$343.0 million in 2026.
• The last three Interest Expenses figures came in at -$343.0 million (Q1 2026), -$304.0 million (Q4 2025), and -$281.0 million (Q3 2025), per Business Quant data.